Three medications approved to treat mild to moderate Alzheimer's—don­epezil (Aricept and generic), galantamine (Razadyne and generic), and rivastigmine (Exelon and generic)—reduce the ...

The FDA has since approved three drugs for the treatment of mild to moderate AD: Donepezil (Aricept) was approved in 1996, Rivastigmine (Exelon) was approved in 2000, and galantamine (Reminyl) was ...

although the results of one tantalizing study conducted by Stanford University researchers showed that a small group of middle-aged pilots given Aricept did better on flight simulation tests ...

In particular, the ChEIs galantamine (Razadyne) and donepezil (Aricept) appeared to help arrest the progression of symptoms related to Lewy body dementia, researchers found. ChEIs also were ...

Heart palpitations at night, which seem to start when you settle into bed, may be noticeable enough to keep you awake. Find ...

Foscenvivint is under development for the treatment of HCV or HBV or NASH-induced decompensated cirrhosis, leukemia such as acute myeloid leukemia (AML), neuroendocrine tumors, ch ...

Reality orientation has its roots in a technique used with confused older people to help them engage in, and connect with, ...

They tried memantine and Aricept, drugs for moderate to severe Alzheimer’s that can help with confusion and memory loss. Neither drug helped, and the side effects were intolerable. Today ...

Specific medications in this class include: Donepezil (Aricept, Adlarity). Rivastigmine (Exelon). Galantamine (Razadyne ER). “Such meds have been known to help 40% of patients slow the decline for six ...

Many dementia medications have at least two names: a name for the main substance in the medication, such as donepezil a brand name, such as Aricept. * Slow-release capsules release the medication into ...

甜菜根，以其鲜艳的红色而闻名，是大脑健康的重要守护者。它富含硝酸盐，这种成分在体内转化为一氧化氮，能够促进血管的扩张，改善大脑的血液循环。良好的血液循环意味着大脑能够获得更多的氧气和营养，从而支持神经元的健康，减缓阿尔茨海默病的进展。

Foscenvivint is under clinical development by Eisai and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I drugs for Prostate Cancer have a 76% phase transition success rate ...